Skip to main content
Clinical Trials/NCT03195361
NCT03195361
Completed
N/A

Multicenter, Prospective, Non-randomized, Single-arm, Interventional Study for the Evaluation of the Safety and Preformance of the SRS Device for the Treatment of Pelvic Organ Prolapse

Lyra Medical Ltd.3 sites in 1 country50 target enrollmentMarch 2016

Overview

Phase
N/A
Intervention
Not specified
Conditions
Anterior Vaginal Wall Prolapse With/Without Apical/Uterine Descent
Sponsor
Lyra Medical Ltd.
Enrollment
50
Locations
3
Primary Endpoint
No unexpected serious adverse device related events
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

A prospective, single arm, multi-center clinical study to evaluate the safety and performance of the SRS (Lyra Medical) vaginal mesh in POP patients

Detailed Description

The SRS implant is intended for transvaginal surgical treatment of anterior vaginal wall prolapse with or without vaginal apex/uterine prolapses

Registry
clinicaltrials.gov
Start Date
March 2016
End Date
December 20, 2020
Last Updated
5 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Sponsor
Lyra Medical Ltd.
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient has signed the informed consent form and is willing to participate in the clinical study and data collection.
  • Patient age is between 50 and 75 years old
  • POP-Q: Aa and/or Ba is at least -1

Exclusion Criteria

  • Patient is pregnant or breastfeeding
  • Patient is suffering from active infection (on antibiotic therapy)
  • Patient is planning vaginal delivery
  • Patient had previous vaginal mesh surgery
  • Patient is in high risk for surgery (evidence of clinically significant cardiovascular, renal, hepatic, coagulatory or respiratory diseases).
  • Any condition that in the judgment of the investigators would interfere with the subject's ability to provide informed consent, comply with study instructions, place the subject at increased risk, or which might confound interpretation of study results.
  • Malignancy.
  • Known hypersensitivity to PEEK and/or polypropylene materials.
  • Participation in another investigational trial that has not completed the primary endpoint or interferes with study participation.
  • Diagnosed with mental or emotional disturbance.

Outcomes

Primary Outcomes

No unexpected serious adverse device related events

Time Frame: 36 months

Improvement in POP-Q point C:

Time Frame: 36 months

Point C at -5 or less

Improvement in POP-Q points Aa and Ba

Time Frame: 36 months

Points Aa and\\or Ba are less than -1

Secondary Outcomes

  • Achieving normal urinary function:(36 Months)
  • Improvement in Quality Of Life (QoL)(36 Months)

Study Sites (3)

Loading locations...

Similar Trials